Article
Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
European journal of clinical pharmacology - 1 Jan 1992
Nielsen K K, Brøsen K, Gram L F
Abstract excerpt
After an initial placebo week, 37 depressed inpatients were treated with the fixed dose of 75 mg clomipramine b.d. A sparteine test was carried out during the placebo period and again during the second week of active therapy. Blood for drug assay was collected at the end of the inter-dose interval in the (morning) at weekly intervals. Clomipramine and four metabolites (desmethylclomipramine,...
Topics
- Adult
- Aged
- Clomipramine
- Cytochrome P-450 Enzyme System
- Debrisoquin
- Depression
- Female
- Humans
- Male
- Middle Aged
- Oxidation-Reduction
- Phenotype